Results 161 to 170 of about 1,359,668 (353)

Herbo-vitamin medicine Livogrit Vital ameliorates isoniazid induced liver injury (IILI) in human liver (HepG2) cells by decreasing isoniazid accumulation and oxidative stress driven hepatotoxicity

BMC Complementary Medicine and Therapies
Background Tuberculosis (TB) is a leading cause of infection related mortality. Isoniazid is one of the frontline drugs for anti-TB therapy. Hepatotoxicity induced by isoniazid is a major cause of drug-discontinuation which may lead to development of ...
Acharya Balkrishna, Vivek Gohel, Meenu Tomer, Rishabh Dev, Anurag Varshney   +4 more
doaj   +1 more source

Bacterial targets and antibiotics: genome-based drug discovery

, 1999
C. Gray, Wolfgang Keck
openalex   +2 more sources

Molecules for the millennium: how will they look? New drug discovery year 2000 [PDF]

, 2000
Edward A. Sausville, J I Johnson
openalex   +1 more source

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

Molecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero, Alejandro Belmonte‐Fernández, Mónica González‐Moreno, Laura Rodríguez‐Cordero, Begoña Pérez‐Valderrama, Joaquín Herrero‐Ruíz, Francisco Romero, Carmen Sáez, Miguel Á. Japón   +8 more
wiley   +1 more source

Correction to: Pharmacological inhibition of nSMase2 reduces brain exosome release and α-synuclein pathology in a Parkinson’s disease model

Molecular Brain, 2021
Chunni Zhu, Tina Bilousova, Samantha Focht, Michael Jun, Chris Jean Elias, Mikhail Melnik, Sujyoti Chandra, Jesus Campagna, Whitaker Cohn, Asa Hatami, Patricia Spilman, Karen Hoppens Gylys, Varghese John   +12 more
doaj   +1 more source

A paradigm for drug discovery employing encoded combinatorial libraries.

, 1995
Jonathan J. Burbaum, Michael Ohlmeyer, Jocelyn Reader, Ian Henderson, Lawrence W. Dillard, G Li, Troy L. Randle, N H Sigal, Daniel Chelsky, John J. Baldwin   +9 more
openalex   +1 more source

Unveiling unique protein and phosphorylation signatures in lung adenocarcinomas with and without ALK, EGFR, and KRAS genetic alterations

Molecular Oncology, EarlyView.
Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi, Mirjam Balbisi, Simon Sugár, Lóránd Váncza, Eszter Regős, Ilona Kovalszky, Ibolya Laczó, Tünde Harkó, Gábor Kecskeméti, Zoltán Szabó, Judit Moldvay, László Drahos, Lilla Turiák   +12 more
wiley   +1 more source

Impact of genomics on drug discovery and clinical medicine [PDF]

, 2000
Gérard Emilien, Michel Ponchon, Carlos Caldas, Ole Isacson, J.M. Maloteaux   +4 more
openalex   +1 more source

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

Molecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh, Liping Su, Suet Lin Chia, Xiaohe Tian, Haslina Ahmad, Martin R. Gill   +5 more
wiley   +1 more source

Viral antichemokines: from pathogenesis to drug discovery [PDF]

, 2000
Philip M. Murphy
openalex   +1 more source